Startups · 27. 10. 2026.1 min read

Orphan Therapeutics Accelerator In-Licenses Investigational Gene Therapy Program for Ornithine Transcarbamylase Deficiency from UCL Ventures and Children's Medical Research Institute

Lokalni automatski prijevod · Izvorni jezik izvora

Illustration generated by Business News; it is not a source photograph.

Sažetak

OTXL-101, a promising therapy in development for a severe, rare pediatric metabolic condition, becomes the first pipeline program to be in-licensed by Orphan Therapeutics Accelerator (OTXL) CAMBRIDGE, Mass., Oct. 27,…

Izvorni jezik izvora: PR Newswire UK — News ReleasesPročitajte original →